CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes.
CGM
Cardiovascular disease
Chronic kidney disease
Diabetes
Finerenone
GLP-1 RA
Guidelines
Heart failure
MASLD
NAFLD
Obesity
SGLT2 inhibitor
Teplizumab
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
19 Mar 2024
19 Mar 2024
Historique:
received:
20
02
2024
accepted:
26
02
2024
medline:
20
3
2024
pubmed:
20
3
2024
entrez:
20
3
2024
Statut:
epublish
Résumé
The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. This reference congress served as a platform for in-depth discussions and exchange on recently completed outcomes trials including dapagliflozin (DAPA-MI), semaglutide (SELECT and STEP-HFpEF) and bempedoic acid (CLEAR Outcomes), and the advances they represent in reducing the risk of major adverse cardiovascular events (MACE), improving metabolic outcomes, and treating obesity-related heart failure with preserved ejection fraction (HFpEF). A broad audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians participated in online discussions on guideline updates for the management of cardiovascular disease (CVD) in diabetes, heart failure (HF) and chronic kidney disease (CKD); advances in the management of type 1 diabetes (T1D) and its comorbidities; advances in the management of CKD with SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists (nsMRAs); and advances in the treatment of obesity with GLP-1 and dual GIP/GLP-1 receptor agonists. The association of diabetes and obesity with nonalcoholic steatohepatitis (NASH; metabolic dysfunction-associated steatohepatitis, MASH) and cancer and possible treatments for these complications were also explored. It is generally assumed that treatment of chronic diseases is equally effective for all patients. However, as discussed at the Summit, this assumption may not be true. Therefore, it is important to enroll patients from diverse racial and ethnic groups in clinical trials and to analyze patient-reported outcomes to assess treatment efficacy, and to develop innovative approaches to tailor medications to those who benefit most with minimal side effects. Other keys to a successful management of diabetes and comorbidities, including dementia, entail the use of continuous glucose monitoring (CGM) technology and the implementation of appropriate patient-physician communication strategies. The 10th Cardiovascular Outcome Trial Summit will be held virtually on December 5-6, 2024 ( http://www.cvot.org ).
Identifiants
pubmed: 38504284
doi: 10.1186/s12933-024-02180-8
pii: 10.1186/s12933-024-02180-8
doi:
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
104Informations de copyright
© 2024. The Author(s).
Références
Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.
pubmed: 34879977
doi: 10.1016/j.diabres.2021.109119
Federation WO. World Obesity Atlas 2023. 2023.
Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17(1):83.
pubmed: 29884191
pmcid: 5994068
doi: 10.1186/s12933-018-0728-6
Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13–27.
pubmed: 28604169
doi: 10.1056/NEJMoa1614362
Rick Turner J. FDA’s New Guidance for Industry addressing evaluation of the safety of new drugs for improving Glycemic Control: a Case Study in Regulatory Science. Ther Innov Regul Sci. 2021;55(1):1–5.
pubmed: 33085070
doi: 10.1007/s43441-020-00211-6
FDA. Guidance for Industry Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes - Guidance Document2008. Available from: https://www.regulations.gov/document/FDA-2008-D-0118-0029 .
Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, Progress, and possibilities. Clin J Am Soc Nephrology: CJASN. 2017;12(12):2032–45.
doi: 10.2215/CJN.11491116
American Diabetes Association. Standards of medical care in diabetes—2021. Diabetes Care. 2021;44(1):1–S232.
Wen CP, Chang CH, Tsai MK, Lee JH, Lu PJ, Tsai SP, et al. Diabetes with early kidney involvement may shorten life expectancy by 16 years. Kidney Int. 2017;92(2):388–96.
pubmed: 28577854
doi: 10.1016/j.kint.2017.01.030
Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20(5):853–72.
pubmed: 29520964
doi: 10.1002/ejhf.1170
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26.
pubmed: 23992601
doi: 10.1056/NEJMoa1307684
White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35.
pubmed: 23992602
doi: 10.1056/NEJMoa1305889
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of Sitagliptin on Cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–42.
pubmed: 26052984
doi: 10.1056/NEJMoa1501352
Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular events in adults with type 2 diabetes and High Cardiovascular and renal risk: the CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69–79.
pubmed: 30418475
doi: 10.1001/jama.2018.18269
Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, et al. Effect of Linagliptin vs glimepiride on major adverse Cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA Randomized Clinical Trial. JAMA. 2019;322(12):1155–66.
pubmed: 31536101
doi: 10.1001/jama.2019.13772
Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al. Lixisenatide in patients with type 2 diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373(23):2247–57.
pubmed: 26630143
doi: 10.1056/NEJMoa1509225
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.
pubmed: 27633186
doi: 10.1056/NEJMoa1607141
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and Cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.
pubmed: 27295427
pmcid: 4985288
doi: 10.1056/NEJMoa1603827
Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly Exenatide on Cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–39.
pubmed: 28910237
pmcid: 9792409
doi: 10.1056/NEJMoa1612917
Hernandez AF, Green JB, Janmohamed S, D’Agostino RB, Sr., Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet (London England). 2018;392(10157):1519–29.
pubmed: 30291013
doi: 10.1016/S0140-6736(18)32261-X
Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and renal outcomes with Efpeglenatide in Type 2 diabetes. N Engl J Med. 2021;385(10):896–907.
pubmed: 34215025
doi: 10.1056/NEJMoa2108269
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.
pubmed: 28605608
doi: 10.1056/NEJMoa1611925
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57.
pubmed: 30415602
doi: 10.1056/NEJMoa1812389
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.
pubmed: 26378978
doi: 10.1056/NEJMoa1504720
Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular outcomes with Ertugliflozin in Type 2 diabetes. N Engl J Med. 2020;383(15):1425–35.
pubmed: 32966714
doi: 10.1056/NEJMoa2004967
Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129–39.
pubmed: 33200891
doi: 10.1056/NEJMoa2030186
McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
pubmed: 31535829
doi: 10.1056/NEJMoa1911303
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with Empagliflozin in Heart failure. N Engl J Med. 2020;383(15):1413–24.
pubmed: 32865377
doi: 10.1056/NEJMoa2022190
Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117–28.
pubmed: 33200892
doi: 10.1056/NEJMoa2030183
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in Heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–61.
pubmed: 34449189
doi: 10.1056/NEJMoa2107038
Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in Heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089–98.
pubmed: 36027570
doi: 10.1056/NEJMoa2206286
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.
pubmed: 30990260
doi: 10.1056/NEJMoa1811744
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46.
pubmed: 32970396
doi: 10.1056/NEJMoa2024816
Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117–27.
pubmed: 36331190
doi: 10.1056/NEJMoa2204233
Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252–63.
pubmed: 34449181
doi: 10.1056/NEJMoa2110956
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on chronic kidney Disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–29.
pubmed: 33264825
doi: 10.1056/NEJMoa2025845
Filippatos G, Anker SD, Pitt B, Rossing P, Joseph A, Kolkhof P, et al. Finerenone and Heart failure outcomes by kidney Function/Albuminuria in chronic kidney disease and diabetes. JACC Heart Fail. 2022;10(11):860–70.
pubmed: 36328655
doi: 10.1016/j.jchf.2022.07.013
James S, Erlinge D, Storey RF, McGuire DK, Belder Md, Eriksson N, et al. Dapagliflozin in myocardial infarction without diabetes or heart failure. NEJM Evid. 2024;3:EVIDoa2300286.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.
pubmed: 33567185
doi: 10.1056/NEJMoa2032183
Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet (London England). 2021;397(10278):971–84.
pubmed: 33667417
doi: 10.1016/S0140-6736(21)00213-0
Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of Subcutaneous Semaglutide vs Placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403–13.
pubmed: 33625476
doi: 10.1001/jama.2021.1831
Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued Weekly Subcutaneous Semaglutide vs Placebo on Weight loss maintenance in adults with overweight or obesity: the STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414–25.
pubmed: 33755728
doi: 10.1001/jama.2021.3224
Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet (London England). 2021;398(10295):143–55.
pubmed: 34186022
doi: 10.1016/S0140-6736(21)01324-6
Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus Semaglutide once Weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–15.
pubmed: 34170647
doi: 10.1056/NEJMoa2107519
Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet (London England). 2021;398(10300):583–98.
pubmed: 34370970
doi: 10.1016/S0140-6736(21)01443-4
Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet (London England). 2021;398(10313):1811–24.
pubmed: 34672967
doi: 10.1016/S0140-6736(21)02188-7
Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, et al. Effect of Subcutaneous Tirzepatide vs Placebo added to titrated insulin glargine on Glycemic Control in patients with type 2 diabetes: the SURPASS-5 Randomized Clinical Trial. JAMA. 2022;327(6):534–45.
pubmed: 35133415
pmcid: 8826179
doi: 10.1001/jama.2022.0078
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once Weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–16.
pubmed: 35658024
doi: 10.1056/NEJMoa2206038
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–32.
pubmed: 37952131
doi: 10.1056/NEJMoa2307563
Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069–84.
pubmed: 37622681
doi: 10.1056/NEJMoa2306963
Vekic J, Stefanovic A, Zeljkovic A. Obesity and dyslipidemia: a review of current evidence. Curr Obes Rep. 2023;12(3):207–22.
pubmed: 37410248
doi: 10.1007/s13679-023-00518-z
Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet (London England). 2015;385(9976):1397–405.
pubmed: 25579834
doi: 10.1016/S0140-6736(14)61368-4
Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy-european Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012–22.
pubmed: 25694464
pmcid: 4416140
doi: 10.1093/eurheartj/ehv043
Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016;7:13457.
pubmed: 27892461
pmcid: 5133702
doi: 10.1038/ncomms13457
Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic Acid and Cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353–64.
pubmed: 36876740
doi: 10.1056/NEJMoa2215024
Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Skra J, et al. Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2016;15:33.
pubmed: 26892706
pmcid: 4758171
doi: 10.1186/s12933-016-0357-x
Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Skra J, et al. Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the diabetes and Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2017;16(1):35.
pubmed: 28284218
pmcid: 5346258
doi: 10.1186/s12933-017-0508-8
Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Lalic K, et al. Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2018;17(1):30.
pubmed: 29458368
pmcid: 5819256
doi: 10.1186/s12933-018-0667-2
Schnell O, Standl E, Catrinoiu D, Itzhak B, Lalic N, Rahelic D, et al. Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2019;18(1):30.
pubmed: 30857522
pmcid: 6410488
doi: 10.1186/s12933-019-0822-4
Schnell O, Standl E, Cos X, Heerspink HJ, Itzhak B, Lalic N, et al. Report from the 5th cardiovascular outcome trial (CVOT) summit. Cardiovasc Diabetol. 2020;19(1):47.
pubmed: 32303223
pmcid: 7165375
doi: 10.1186/s12933-020-01022-7
Schnell O, Cos X, Cosentino F, Forst T, Giorgino F, Heersprink HJL, et al. Report from the CVOT Summit 2020: new cardiovascular and renal outcomes. Cardiovasc Diabetol. 2021;20(1):75.
pubmed: 33789663
pmcid: 8010779
doi: 10.1186/s12933-021-01254-1
Schnell O, Battelino T, Bergenstal R, Blüher M, Böhm M, Brosius F, et al. Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. Cardiovasc Diabetol. 2022;21(1):50.
pubmed: 35395808
pmcid: 8990484
doi: 10.1186/s12933-022-01481-0
Schnell O, Battelino T, Bergenstal R, Birkenfeld AL, Ceriello A, Cheng A, et al. CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes. Cardiovasc Diabetol. 2023;22(1):59.
pubmed: 36927451
pmcid: 10019427
doi: 10.1186/s12933-023-01788-6
Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J. 2011;33(2):176–82.
pubmed: 21900289
doi: 10.1093/eurheartj/ehr352
Ceriello A, Rodbard HW, Battelino T, Brosius F, Cosentino F, Green J, et al. Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop. Cardiovasc Diabetol. 2023;22(1):277.
pubmed: 37833776
pmcid: 10576408
doi: 10.1186/s12933-023-01993-3
Shi Q, Nong K, Vandvik PO, Guyatt GH, Schnell O, Rydén L, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ (Clinical Res ed). 2023;381:e074068.
Elliott J, Lawrence R, Minx JC, Oladapo OT, Ravaud P, Tendal Jeppesen B, et al. Decision makers need constantly updated evidence synthesis. Nature. 2021;600(7889):383–5.
pubmed: 34912079
doi: 10.1038/d41586-021-03690-1
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627–39.
pubmed: 37622666
doi: 10.1093/eurheartj/ehad195
Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043–140.
pubmed: 37622663
doi: 10.1093/eurheartj/ehad192
Kunutsor SK, Khunti K, Seidu S. Racithnic and regional differences in the effect of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes: a systematic review and meta-analysis of cardiovascular outcome trials. J R Soc Med. 2023:1410768231198442.
Kelly RC, Holt RIG, Desborough L, Majidi S, Town M, Naranjo D et al. The psychosocial burdens of living with diabetes. Diabet Medicine: J Br Diabet Association. 2023:e15219.
Federation ID. IDF Annual Report 2022. 2022.
Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022;12(1):7–11.
pubmed: 35529086
doi: 10.1016/j.kisu.2021.11.003
Collaboration GCKD. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet (London England). 2020;395(10225):709–33.
doi: 10.1016/S0140-6736(20)30045-3
de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes management in chronic kidney disease: a Consensus Report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO). Diabetes Care. 2022;45(12):3075–90.
pubmed: 36189689
pmcid: 9870667
doi: 10.2337/dci22-0027
Seidu S, Cos X, Topsever P. Self-rated knowledge and competence regarding the management of chronic kidney disease in primary care: a cross-sectional European survey of primary care professionals. Prim Care Diabetes. 2023;17(1):19–26.
pubmed: 36513582
doi: 10.1016/j.pcd.2022.11.013
Schultes B, Emmerich S, Kistler AD, Mecheri B, Schnell O, Rudofsky G. Impact of albumin-to-creatinine ratio point-of-care testing on the diagnosis and management of Diabetic kidney disease. J Diabetes Sci Technol. 2023;17(2):428–38.
pubmed: 34709065
doi: 10.1177/19322968211054520
Nephrology ISo. Chronic Kidney Disease (CKD) Early Identification and Intervention in Primary Care. 2023.
Group KDIGOKDW. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in chronic kidney disease. Kidney Int. 2022;102(5s):1–s127.
von Scholten BJ, Kreiner FF, Rasmussen S, Rossing P, Idorn T. The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice. Ther Adv Endocrinol Metab. 2022;13:20420188221112490.
Consortium, NDoPHRSGSiM-AC-RT. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet (London England). 2022;400(10365):1788–801.
doi: 10.1016/S0140-6736(22)02074-8
Heerspink HJL, Kiyosue A, Wheeler DC, Lin M, Wijkmark E, Carlson G, et al. Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial. Lancet (London England). 2023;402(10416):2004–17.
pubmed: 37931629
doi: 10.1016/S0140-6736(23)02230-4
Bakris GL, Yang YF, McCabe JM, Liu JR, Tan XJ, Benn VJ, et al. Efficacy and safety of Ocedurenone: Subgroup Analysis of the BLOCK-CKD Study. Am J Hypertens. 2023;36(11):612–8.
pubmed: 37471468
pmcid: 10570658
doi: 10.1093/ajh/hpad066
Sarafidis P, Agarwal R, Pitt B, Wanner C, Filippatos G, Boletis J, et al. Outcomes with Finerenone in participants with stage 4 CKD and type 2 diabetes: a FIDELITY Subgroup Analysis. Clin J Am Soc Nephrology: CJASN. 2023;18(5):602–12.
doi: 10.2215/CJN.0000000000000149
Pearson-Stuttard J, Zhou B, Kontis V, Bentham J, Gunter MJ, Ezzati M. Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diabetes Endocrinol. 2018;6(6):e6–e15.
pubmed: 29803268
pmcid: 5982644
doi: 10.1016/S2213-8587(18)30150-5
Collaborators GCRF. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the global burden of Disease Study 2019. Lancet (London England). 2022;400(10352):563–91.
doi: 10.1016/S0140-6736(22)01438-6
Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85–97.
pubmed: 21252989
pmcid: 3518031
doi: 10.1038/nri2921
Rios Garcia M, Steinbauer B, Srivastava K, Singhal M, Mattijssen F, Maida A, et al. Acetyl-CoA carboxylase 1-Dependent protein acetylation controls breast Cancer metastasis and recurrence. Cell Metab. 2017;26(6):842–55e5.
pubmed: 29056512
doi: 10.1016/j.cmet.2017.09.018
Zhang AMY, Xia YH, Lin JSH, Chu KH, Wang WCK, Ruiter TJJ, et al. Hyperinsulinemia acts via acinar insulin receptors to initiate pancreatic cancer by increasing digestive enzyme production and inflammation. Cell Metabol. 2023;35(12):2119–35e5.
doi: 10.1016/j.cmet.2023.10.003
Chettouh H, Lequoy M, Fartoux L, Vigouroux C, Desbois-Mouthon C. Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma. Liver Int. 2015;35(10):2203–17.
pubmed: 26123841
doi: 10.1111/liv.12903
Tacke F, Puengel T, Loomba R, Friedman SL. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. J Hepatol. 2023;79(2):552–66.
pubmed: 37061196
doi: 10.1016/j.jhep.2023.03.038
Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497–509.
pubmed: 38324483
doi: 10.1056/NEJMoa2309000
Harrison SA, Ruane PJ, Freilich B, Neff G, Patil R, Behling C, et al. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. JHEP Rep. 2023;5(1):100563.
pubmed: 36644237
doi: 10.1016/j.jhepr.2022.100563
Loomba R, Sanyal AJ, Kowdley KV, Bhatt DL, Alkhouri N, Frias JP, et al. Randomized, controlled trial of the FGF21 Analogue Pegozafermin in NASH. N Engl J Med. 2023;389(11):998–1008.
pubmed: 37356033
pmcid: 10718287
doi: 10.1056/NEJMoa2304286
Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kjær MS, Krarup N, et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(6):511–22.
pubmed: 36934740
pmcid: 10792518
doi: 10.1016/S2468-1253(23)00068-7
A study of tirzepatide (LY3298176). in participants with nonalcoholic steatohepatitis (NASH) (SYNERGY-NASH) [Internet]. 2019. Available from: https://clinicaltrials.gov/ct2/show/NCT04166773 .
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542–56.
pubmed: 37364790
doi: 10.1016/j.jhep.2023.06.003
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2024;29(1):101133.
pubmed: 37364816
doi: 10.1016/j.aohep.2023.101133
Zhang Q, Delessa CT, Augustin R, Bakhti M, Colldén G, Drucker DJ, et al. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. Cell Metab. 2021;33(4):833–44e5.
pubmed: 33571454
pmcid: 8035082
doi: 10.1016/j.cmet.2021.01.015
Liskiewicz A, Khalil A, Liskiewicz D, Novikoff A, Grandl G, Maity-Kumar G, et al. Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice. Nat Metab. 2023;5(12):2075–85.
pubmed: 37946085
pmcid: 10730394
doi: 10.1038/s42255-023-00931-7
Habegger KM, Heppner KM, Geary N, Bartness TJ, DiMarchi R, Tschöp MH. The metabolic actions of glucagon revisited. Nat Rev Endocrinol. 2010;6(12):689–97.
pubmed: 20957001
pmcid: 3563428
doi: 10.1038/nrendo.2010.187
Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet (London England). 2023;402(10401):529–44.
pubmed: 37385280
doi: 10.1016/S0140-6736(23)01053-X
Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, et al. Triple–hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514–26.
pubmed: 37366315
doi: 10.1056/NEJMoa2301972
Aroda VR, Aberle J, Bardtrum L, Christiansen E, Knop FK, Gabery S, et al. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. Lancet (London England). 2023;402(10403):693–704.
pubmed: 37385279
doi: 10.1016/S0140-6736(23)01127-3
Frias JP, Hsia S, Eyde S, Liu R, Ma X, Konig M, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet (London England). 2023;402(10400):472–83.
pubmed: 37369232
doi: 10.1016/S0140-6736(23)01302-8
Schabert J, Browne JL, Mosely K, Speight J. Social stigma in diabetes: a framework to understand a growing problem for an increasing epidemic. Patient. 2013;6(1):1–10.
pubmed: 23322536
doi: 10.1007/s40271-012-0001-0
Nutter S, Eggerichs LA, Nagpal TS, Ramos Salas X, Chin Chea C, Saiful S, et al. Changing the global obesity narrative to recognize and reduce weight stigma: a position statement from the World Obesity Federation. Obes Rev. 2024;25(1):e13642.
pubmed: 37846179
doi: 10.1111/obr.13642
Albury C, Webb H, Stokoe E, Ziebland S, Koshiaris C, Lee JJ, et al. Relationship between Clinician Language and the success of behavioral weight loss interventions: a mixed-methods cohort study. Ann Intern Med. 2023;176(11):1437–47.
pubmed: 37931269
doi: 10.7326/M22-2360
Ogle GD, Wang F, Gregory GA, Maniam J. Type 1 diabetes mellitus estimates in children and adults. Brussels, Belgium: International Diabetes Federation; 2022.
Gregory GA, Robinson TIG, Linklater SE, Wang F, Colagiuri S, de Beaufort C, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol. 2022;10(10):741–60.
pubmed: 36113507
doi: 10.1016/S2213-8587(22)00218-2
Quinn LM, Wong FS, Narendran P. Environmental determinants of type 1 diabetes: from Association to proving causality. Front Immunol. 2021;12:737964.
pubmed: 34659229
pmcid: 8518604
doi: 10.3389/fimmu.2021.737964
Hummel S, Carl J, Friedl N, Winkler C, Kick K, Stock J, et al. Children diagnosed with presymptomatic type 1 diabetes through public health screening have milder diabetes at clinical manifestation. Diabetologia. 2023;66(9):1633–42.
pubmed: 37329450
pmcid: 10390633
doi: 10.1007/s00125-023-05953-0
Sims EK, Bundy BN, Stier K, Serti E, Lim N, Long SA, et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med. 2021;13:583.
doi: 10.1126/scitranslmed.abc8980
Ramos EL, Dayan CM, Chatenoud L, Sumnik Z, Simmons KM, Szypowska A, et al. Teplizumab and β-Cell function in newly diagnosed type 1 diabetes. N Engl J Med. 2023;389(23):2151–61.
pubmed: 37861217
doi: 10.1056/NEJMoa2308743
Elliott J, Sloan G, Stevens L, Selvarajah D, Cruccu G, Gandhi RA, et al. Female sex is a risk factor for painful diabetic peripheral neuropathy: the EURODIAB prospective diabetes complications study. Diabetologia. 2024;67(1):190–8.
pubmed: 37870649
doi: 10.1007/s00125-023-06025-z
Tesfaye S, Sloan G, Petrie J, White D, Bradburn M, Julious S, et al. Comparison of Amitriptyline supplemented with Pregabalin, Pregabalin supplemented with Amitriptyline, and duloxetine supplemented with Pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial. Lancet (London England). 2022;400(10353):680–90.
pubmed: 36007534
doi: 10.1016/S0140-6736(22)01472-6
Ziegler D, Tesfaye S, Spallone V, Gurieva I, Al Kaabi J, Mankovsky B, et al. Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: International expert consensus recommendations. Diabetes Res Clin Pract. 2022;186:109063.
pubmed: 34547367
doi: 10.1016/j.diabres.2021.109063
El-Nahas MR, Elkannishy G, Abdelhafez H, Elkhamisy ET, El-Sehrawy AA. Oral alpha Lipoic Acid Treatment for Symptomatic Diabetic Peripheral Neuropathy: a Randomized double-blinded placebo-controlled study. Endocr Metab Immune Disord Drug Targets. 2020;20(9):1531–4.
pubmed: 32370731
doi: 10.2174/1871530320666200506081407
Nguyen N, Takemoto JK. A case for alpha-lipoic acid as an Alternative Treatment for Diabetic Polyneuropathy. J Pharm Pharm Sci. 2018;21(1s):177s–91s.
pubmed: 30139425
doi: 10.18433/jpps30100
Ziegler D, Low PA, Litchy WJ, Boulton AJ, Vinik AI, Freeman R, et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. 2011;34(9):2054–60.
pubmed: 21775755
pmcid: 3161301
doi: 10.2337/dc11-0503
Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Experimental and clinical endocrinology & diabetes: official journal. German Soc Endocrinol [and] German Diabetes Association. 2008;116(10):600–5.
doi: 10.1055/s-2008-1065351
Celis-Morales CA, Franzén S, Eeg-Olofsson K, Nauclér E, Svensson AM, Gudbjornsdottir S, et al. Type 2 diabetes, Glycemic Control, and their Association with Dementia and its major subtypes: findings from the Swedish National Diabetes Register. Diabetes Care. 2022;45(3):634–41.
pubmed: 35077536
doi: 10.2337/dc21-0601
Hu J, Fang M, Pike JR, Lutsey PL, Sharrett AR, Wagenknecht LE, et al. Prediabetes, intervening diabetes and subsequent risk of dementia: the atherosclerosis risk in communities (ARIC) study. Diabetologia. 2023;66(8):1442–9.
pubmed: 37221246
pmcid: 10467356
doi: 10.1007/s00125-023-05930-7
Sugimoto T, Tokuda H, Miura H, Kawashima S, Ando T, Kuroda Y, et al. Cross-sectional association of metrics derived from continuous glucose monitoring with cognitive performance in older adults with type 2 diabetes. Diabetes Obes Metab. 2023;25(1):222–8.
pubmed: 36082514
doi: 10.1111/dom.14866
Li R, Geng T, Li L, Lu Q, Li R, Chen X, et al. Associations of glucose metabolism status with brain macrostructure and microstructure: findings from the UK Biobank. J Clin Endocrinol Metab. 2023;109(1):e234–e42.
pubmed: 37497611
doi: 10.1210/clinem/dgad442
Monereo-Sánchez J, Jansen JFA, Köhler S, van Boxtel MPJ, Backes WH, Stehouwer CDA, et al. The association of prediabetes and type 2 diabetes with hippocampal subfields volume: the Maastricht study. Neuroimage Clin. 2023;39:103455.
pubmed: 37356423
pmcid: 10310479
doi: 10.1016/j.nicl.2023.103455
Lu J, Wang C, Shen Y, Chen L, Zhang L, Cai J, et al. Time in Range in Relation to all-cause and Cardiovascular Mortality in patients with type 2 diabetes: a prospective cohort study. Diabetes Care. 2021;44(2):549–55.
pubmed: 33097560
doi: 10.2337/dc20-1862